• Biology
  • Published 2003

Cloning, Expression, and Renaturation Studies of Reteplase

@inproceedings{Zhao2003CloningEA,
  title={Cloning, Expression, and Renaturation Studies of Reteplase},
  author={Youchun Zhao and Wang Ge and Young Hee Kong and Changkai Zhang},
  year={2003}
}
Recombinant human tissue plasminogen activator deletion mutein (Reteplase) is a clinically promising thrombolytic drug. Reteplase cDNA was subcloned into a bacteria expression system, and the resultant recombinant was biologically characterized. The Reteplase was expressed in Escherichia coli as an inclusion body, and the downstream processes of the Reteplase inclusion body included denaturation, renaturation, and purification. A protein disulfide isomerase (PDI) was used to assist the… CONTINUE READING

Figures from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Confirm biochemical properties of reteplase

Y. Zhao, G. Wang, C. Zhang
  • Sci. Technol. Chem. Ind
  • 2003

A novel engineering clot buster-Reteplase, papers pp. 73 -74

G. Wang, Y. Zhao, +4 authors C. Zhang
  • In Chinese Academy of Engineering, Symposium on Frontiers of Biotechnology and Pharmaceuticals
  • 2001
VIEW 1 EXCERPT

A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1997
VIEW 1 EXCERPT

Tutorial biochemical and pharmacolog comparison of thrombolytic agents

K. A. Stringer
  • Pharmacotherapy
  • 1996
VIEW 1 EXCERPT

Does finding with a nov recombinant plasminogen activator (BM06.022) in patien with acute myocardial infarction: Results of the Germa Recombinant Plasminogen Activator Study

K. L. Neuhaus, R. von Essen, +7 authors W. Meger-Sabelek
  • J. Am. Coll. Cardiol
  • 1994
VIEW 1 EXCERPT